FLT3 and acute myeloid leukemia: Studies involving AML patients with FLT3 mutations at diagnosis, using standard high-dose chemotherapy in combination with FLT3 TKIs such as midostaurin (RATIFY study) (11), sorafenib (SORAML study) (12), and quizartinib (QuANTUM-First study) (13), have shown significantly improved outcomes in terms of relapse-free survival and overall survival compared to standard chemotherapy alone.